JD Supra8d
Transparency Is the Best Medicine: Device Parts Don’t Justify Orange Book Listing
The US Court of Appeals for the Federal Circuit affirmed a district court’s delisting of patents from the Orange Book because the patent claims ...
JD Supra16d
Teva v. Amneal Ruling Interprets Orange Book Listing Statute, Affirms Delisting of Device Patents
On December 20, 2024, the US Court of Appeals for the Federal Circuit released its opinion in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal ...
Medscape16d
Inhaler Device Selection
Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.
BMJ20d
Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study
Objective To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once daily dry powder inhaler, ...
Medscape29d
Effects of Extreme Temperatures on Drug Delivery of Albuterol Sulfate Hydrofluoroalkane Inhalation Aerosols
The manufacturers' reported dose per actuation for both MDIs is 108 µg of albuterol sulfate ... of the inhalers when not allowed to return to room temperature. Proventil HFA and Ventolin HFA ...
news.bloomberglaw29d
Teva Must Delist Asthma-Inhaler Patents, Appeals Court Rules (1)
Amneal beats Teva’s challenge of ruling on some ProAir patents Decision could impact other ‘junk device listings,’ FTC says Five patents related to Teva Pharmaceutical Industries Ltd.’s ProAir HFA ...